Aces Diagnostics
- Company typePrivate
- Founded2024
- HeadquartersPortola Valley, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Aces Diagnostics firmographics
Firmographics- Name
- Aces Diagnostics
- Legal name
- Aces Diagnostics, Inc.
- Website
- https://acesdiagnostics.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Aces Diagnostics industry classification
Industry- Product category
- Clinical Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
- akta.pro secondary industries
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Method Development & Validation (ICH/USP) (HLAGADAB)
Keywords
Where Aces Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Portola Valley
- HQ country
- United States
- HQ region
- North America
Markets served
Aces Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Diagnostic Testing Services: Aces Diagnostics plans to generate revenue through a single blood test for Lyme disease detection. The test will be offered via clinical laboratory partnerships, with commercial launch anticipated in 2027. As a diagnostic test, revenue is expected to come from test fees per sample processed.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
Aces Diagnostics product offering
Product offeringCore offering
Aces Diagnostics develops LYMESEEK, a single blood test that combines proprietary biomarkers with machine learning algorithms to enable earlier, more accurate Lyme disease detection across all stages of infection. The test is designed to run on existing clinical laboratory equipment without requiring special instrumentation and is being validated for FDA regulatory clearance with commercial launch anticipated in 2027.
Product overview
Aces Diagnostics offers a single unified product: LYMESEEK™, a multiplexed immunoassay blood test for Lyme disease detection. The test combines proprietary biomarkers with machine learning algorithms and is designed to run on existing clinical laboratory equipment. Commercial launch is anticipated in 2027 pending FDA regulatory clearance.
Differentiator
Problem solved
Functional benefit
Brands
- LYMESEEK: A clinically validated blood test using multiplexed immunoassay technology combined with machine learning algorithms for improved Lyme disease detection across all stages of disease.
Products and services
- LYMESEEK A single blood test that combines proprietary biomarkers with machine learning to enable earlier, more accurate Lyme disease detection across all stages of infection. Validated on more than 1,000 clinical samples from U.S. and European populations demonstrating greater than 90% accuracy. Designed to run on existing clinical laboratory equipment, requiring only one blood draw.
Quantifiable outcome
- Boston Strategic Partners projects LYMESEEK could reduce Lyme-related healthcare costs by $3.2 Billion annually through earlier diagnosis and intervention
- +2 more outcomes
Companies that use Aces Diagnostics
Customer profileSegments4 records
Ideal customer profiles3 records
Aces Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Aces Diagnostics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- ProtaviocorePartnership with Protavio to develop the LymeSeek diagnostic test for Lyme disease. The collaboration aims to advance the test towards commercialization including FDA submission. The test uses multiplexed immunoassay technology and machine-learning algorithms to improve early detection accuracy.
- RepadocorePartnership with Repado to develop the LymeSeek diagnostic test for Lyme disease. The collaboration aims to advance the test towards commercialization including FDA submission. The test uses multiplexed immunoassay technology and machine-learning algorithms to improve early detection accuracy.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Aces Diagnostics competitors and assessment
Company assessmentBroad incumbents
- Quest Diagnostics: Quest Diagnostics is a major reference laboratory offering Lyme disease serology testing services to physicians and health systems; it represents a potential channel partner and competitor for Aces' clinical laboratory partnership model.
- QIAGEN: QIAGEN is a global molecular diagnostics and sample-prep company with broad infectious disease test menus. While not focused on Lyme, its QIAstat-Dx and molecular diagnostics platforms represent a broader competitive threat in infectious disease testing.
- Labcorp: Labcorp is one of the largest clinical reference laboratories in the U.S. and offers Lyme disease testing services, representing both a potential commercialization partner and an entrenched competitor to LYMESEEK.
- Mérieux NutriSciences (bioMérieux): bioMérieux is a global in vitro diagnostics company with broad infectious disease menus; comparable as a large IVD incumbent whose diagnostic platforms could be used for Lyme serology and molecular testing.
- Bio-Rad Laboratories: Bio-Rad is a large, established life science and clinical diagnostics company that produces quality controls, immunoassay instruments, and infectious disease test kits. Its BioPlex 2200 Lyme menu directly competes with LYMESEEK.
Emerging players
- T2 Biosystems: T2 Biosystems is a small, clinical-stage diagnostics company focused on rapid direct-from-blood detection of infectious disease pathogens. Comparable to Aces as an emerging infectious disease diagnostics player navigating the FDA and clinical launch path.
Direct peers
- Oxford Immunotec: Oxford Immunotec (part of Revvity/PerkinElmer) develops specialized immunology and infectious disease diagnostics, including historically in tick-borne disease testing. Comparable to Aces as a specialty infectious disease diagnostics company.
- EUROIMMUN (Revvity): EUROIMMUN, now part of Revvity (formerly PerkinElmer), offers a broad menu of autoimmune and infectious disease serology tests including Lyme disease immunoassays, directly overlapping with LYMESEEK's multiplexed serology approach.
- Trinity Biotech: Trinity Biotech is a direct peer as a developer and manufacturer of diagnostic test kits for infectious diseases including Lyme disease (e.g., the MarDx line). It is the most directly comparable commercial Lyme diagnostics competitor to Aces' LYMESEEK.
- Zeus Scientific: Zeus Scientific develops and markets immunoassay diagnostic test kits, including FDA-cleared Lyme disease serology tests, directly competing with Aces in the clinical Lyme diagnostics market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Aces Diagnostics social profiles
Digital presenceAces Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aces Diagnostics leadership team
Management profileNumber of profiles
Profiles9 records
Aces Diagnostics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aces Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aces Diagnostics
What does Aces Diagnostics do?
Aces Diagnostics develops LYMESEEK, a single blood test that combines proprietary biomarkers with machine learning algorithms to enable earlier, more accurate Lyme disease detection across all stages of infection. The test is designed to run on existing clinical laboratory equipment without requiring special instrumentation and is being validated for FDA regulatory clearance with commercial launch anticipated in 2027.
Is Aces Diagnostics a public or private company?
Aces Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aces Diagnostics founded?
Aces Diagnostics was founded in 2024. It employs 1 to 10 people.
Where is Aces Diagnostics based?
Aces Diagnostics is headquartered in Portola Valley, United States, in the North America region.
How does Aces Diagnostics make money?
One revenue line is on record: diagnostic Testing Services.
Who are Aces Diagnostics's main competitors?
Broad incumbents on record are Quest Diagnostics, QIAGEN, Labcorp, Mérieux NutriSciences (bioMérieux) and Bio-Rad Laboratories. T2 Biosystems is listed as an emerging player. Direct peers are Oxford Immunotec, EUROIMMUN (Revvity), Trinity Biotech and Zeus Scientific.
Does Aces Diagnostics have an API?
No public API is recorded for Aces Diagnostics.
What industry is Aces Diagnostics in?
Aces Diagnostics's product category is Clinical Diagnostics. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 325413 and its SIC code is 2835.